{"entity":{"id":"aeneas","kind":"trial","name":"AENEAS","aka":[],"tldr":"The trial that showed Hansoh's aumolertinib roughly doubles progression-free survival compared with gefitinib in EGFR-mutant lung cancer.","summary":"429 patients, double blind. Median progression-free survival 19.3 versus 9.9 months (hazard ratio 0.46), consistent across exon 19 and L858R subgroups and in patients with brain metastases; published in the Journal of Clinical Oncology 2022. NMPA first-line approval December 2021. Aumolertinib has since become one of the most prescribed targeted drugs in China.","status":"positive","asOf":"2026-09-10","links":[{"label":"ClinicalTrials.gov NCT03849768","url":"https://clinicaltrials.gov/study/NCT03849768"},{"label":"J Clin Oncol 2022","url":"https://doi.org/10.1200/JCO.21.02641"}],"tags":["china"],"related":["furlong"],"cancers":["nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["egfr"],"drugs":["aumolertinib","gefitinib"],"companies":["hansoh-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-aeneas-j-clin-oncol-2022"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03849768","phase":"3","setting":"First-line EGFR-mutant (exon 19 deletion or L858R) locally advanced or metastatic NSCLC, China: aumolertinib vs gefitinib","sponsor":"Hansoh Pharmaceutical","result":"PFS 19.3 vs 9.9 months, HR 0.46.","started":"2019-02-01","startedType":"actual","yearReported":2022,"enrolled":429,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival","primary":true,"unit":"months","arms":[{"name":"Aumolertinib","n":214,"value":19.3},{"name":"Gefitinib","n":215,"value":9.9}],"hr":0.46,"source":"https://doi.org/10.1200/JCO.21.02641"}]},"route":"/trials/aeneas/","neighbours":{"trial":[{"id":"furlong","kind":"trial","name":"FURLONG","route":"/trials/furlong/"}],"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"drug":[{"id":"aumolertinib","kind":"drug","name":"Aumolertinib","route":"/drugs/aumolertinib/"},{"id":"gefitinib","kind":"drug","name":"Gefitinib","route":"/drugs/gefitinib/"}],"company":[{"id":"hansoh-pharma","kind":"company","name":"Hansoh Pharmaceutical","route":"/companies/hansoh-pharma/"}],"paper":[{"id":"paper-aeneas-j-clin-oncol-2022","kind":"paper","name":"AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations","route":"/key-papers/paper-aeneas-j-clin-oncol-2022/"}]}}